Gilead Sciences Inc GILD:NASDAQ

Last Price$63.99NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/11/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$64.00 (2)
Ask (Size)$64.43 (1)
Day Low / HighN/A - N/A
Volume5.7 M

View Biotechnology IndustryPeer Comparison as of 10/11/2019


Gilead Sciences Inc ( NASDAQ )

Price: $63.99
Change: +0.73 (1.15%)
Volume: 5.7 M
4:00PM ET 10/11/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Celgene Corp ( NASDAQ )

Price: $100.57
Change: +0.76 (0.76%)
Volume: 3.7 M
4:00PM ET 10/11/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Illumina Inc ( NASDAQ )

Price: $302.58
Change: +4.40 (1.48%)
Volume: 681.4 K
3:59PM ET 10/11/2019

Read more news Recent News

Sector Update: Health Care Majors Trade Higher Pre-Bell Friday
9:20AM ET 10/11/2019 MT Newswires

Top Health Care Stocks: JNJ: +1.41% PFE: +1.12% ABT: +0.35% MRK: +0.41% AMGN: +0.16% Health care majors were trading higher pre-bell Friday. Early movers...

Gilead, Galapagos Say 52-Week Data on Rheumatoid Arthritis Treatment Filgotinib Show Consistent Safety Profile
4:52AM ET 10/11/2019 MT Newswires

Gilead Sciences (GILD) and Galapagos NV (GLPG) said late Thursday that 52-week data from two phase 3 trials of filgotinib for moderately-to-severely active...

Gilead Sciences Submits NDA in Japan for Filgotinib for Rheumatoid Arthritis
5:00AM ET 10/08/2019 MT Newswires

Gilead Sciences (GILD), a biopharmaceutical company, said Tuesday it has submitted a new drug application in Japan for filgotinib for the treatment of...

Scotland Accepts Gilead Sciences' Yescarta Blood Cancer Treatment
3:02PM ET 10/07/2019 MT Newswires

Scottish Medicines Consortium, which decides on the cost-effectiveness of medicines, said on Monday Gilead Sciences' (GILD) Yescarta to treat lymphoma, a...

View all Commentary and Analysis

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
4:45PM ET 10/11/2019 Zacks

Gilead Sciences (GILD) closed the most recent trading day at $63.99, moving +1.15% from the...

Why Gilead (GILD) Could Beat Earnings Estimates Again
9:10AM ET 10/11/2019 Zacks

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right...

Monthly Review Of DivGro: September 2019
7:06AM ET 10/10/2019 Seeking Alpha

Sustainable Green Finance May Be The Next Big Thing
2:48PM ET 10/08/2019 Seeking Alpha

Company Profile

Business DescriptionGilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. View company web site for more details
Address333 Lakeside Drive
Foster City, California 94404
Number of Employees11,000
Recent SEC Filing10/03/20194
Chairman & Chief Executive OfficerDaniel O'Day
CFO, Chief Accounting Officer & Executive VPRobin L. Washington
Secretary, Chief Compliance Officer & Executive VPBrett A. Pletcher
Executive Vice President-ResearchWilliam A. Lee

Company Highlights

Price Open$63.95
Previous Close$63.26
52 Week Range$60.32 - 76.44
Market Capitalization$81.0 B
Shares Outstanding1.3 B
SectorHealth Technology
Current Dividend / Yield$0.63 / 3.94%
Dividend Ex-Date09/12/2019
Dividend Pay-Date09/27/2019
Dividend Yield 5 Year AverageN/A
Next Earnings Announcement10/24/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings13.88
Earnings per Share$4.85
Beta vs. S&P 500N/A
Revenue$22.2 B
Net Profit Margin26.72%
Return on Equity26.82%

Analyst Ratings as of 10/10/2019

Consensus RecommendationConsensus Icon
Powered by Factset